Search
Chronic Graft-Versus-Host Disease
go.drugbank.com/conditions/DBCOND0045787Axatilimab
go.drugbank.com/drugs/DB16388ApprovedInvestigational[A264309] Approved treatment options in steroid-refractory cGHVD are limited, and include [ruxolitinib], [ibrutinib], and [belumosudil].
Mild Atopic dermatitis
go.drugbank.com/conditions/DBCOND0025273Rineterkib
go.drugbank.com/drugs/DB17560Investigationalis an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib
Nisevokitug
go.drugbank.com/drugs/DB17561Investigationalantibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib
Mivebresib
go.drugbank.com/drugs/DB21300InvestigationalMivebresib is under investigation in clinical trial NCT04480086 (Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants
Moderate Atopic dermatitis
go.drugbank.com/conditions/DBCOND0025271TL-895
go.drugbank.com/drugs/DB16471Investigational: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B cell malignancies including chronic lymphocytic leukemia), NCT05280509 (recruiting, combination with Ruxolitinib
Severe Alopecia Areata (AA)
go.drugbank.com/conditions/DBCOND0158827